Castle Biosciences, Inc. — Earnings Quality Grade C
CSTL · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 46 days, change -10 days YoY
AR growth -15.3% vs revenue growth 3.7%
Revenue 3.7%, CFFO -0.8%. Cash follows revenue
Expense Quality
Inventory 26.0% vs COGS 18.0%. Normal
CapEx growth 27.2% is >2x revenue growth 3.7%
SG&A/Gross Profit = 83.9%, exceeds 70%
Gross margin 79.4%, change -2.5pp. Stable
Cash Flow Quality
CFFO/NI = -2.66. Below 1.0
FCF $0.0B, FCF/NI = -1.17
Accruals ratio = -15.3%. Low accruals
Cash $0.3B covers debt $0.0B
Balance Sheet Health
Goodwill+Intangibles $0.1B = 21% of equity. Manageable
Interest coverage = -497.8x (<2x). Financial stress
Other assets grew 206.9% vs revenue 3.7%
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -6% YoY. Normal
Manipulation Score
M-Score = -3.47 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor CSTL continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25